Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE versus PIVYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE versus PIVYA.
BUPRENORPHINE vs PIVYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Pivya (pivmecillinam) is a prodrug of mecillinam, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2), leading to defective cell wall formation and cell death.
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
1200 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateBuprenorphine + Torasemide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide."
Clinical Note
moderateBuprenorphine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid."
Clinical Note
moderateBuprenorphine + Furosemide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide."
Clinical Note
moderateTerminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Terminal elimination half-life of 3-4 hours in patients with normal renal function; may be prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
Primarily renal excretion as unchanged drug (approximately 70-80%); biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist
Buprenorphine + Bumetanide
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide."